Hanne Mariën

Ms. Hanne Mariën

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
HMHanne Mariën
Hanne Mariën
EDElien Derveaux
Elien Derveaux
VKVanhove Karolien
Vanhove Karolien
PAPeter Adriaensens
Peter Adriaensens
Michiel ThomeerMichiel Thomeer
Michiel Thomeer
LMLiesbet Mesotten
Liesbet Mesotten
Lung cancer is the leading cause of cancer-related mortality worldwide, with five-year survival rates varying from 3–62%. Screening aims at early detection, but half of the patients are diagnosed in advanced stages, limiting therapeutic possibilities. Positron emission tomography-computed tomography (PET-CT) is an essential technique in lung cancer detection and staging, with a sensitivity reaching 96%. However, since elevated 18F-fluorodeoxyglucose (18F-FDG) uptake is not cancer-specific, PET-CT often fails to discriminate between malignant and non-malignant PET-positive hypermetabolic lesions, with a specificity of only 23%. Furthermore, discrimination between lung cancer types is still impossible without invasive procedures. High mortality and morbidity, low survival rates, and difficulties in early detection, staging, and typing of lung cancer motivate the search for biomarkers to improve the diagnostic process and life expectancy. Metabolomics has emerged as a valuable technique for these pitfalls. Over 150 metabolites have been associated with lung cancer, and several are consistent in their findings of alterations in specific metabolite concentrations. However, there is still more variability than consistency due to the lack of standardized patient cohorts and measurement protocols. This review summarizes the identified metabolic biomarkers for early diagnosis, staging, and typing and reinforces the need for biomarkers to predict disease progression and survival and to support treatment follow-up.

Verified
Journal Article
Open access
PDF file
VKVanhove Karolien
Vanhove Karolien
EDElien Derveaux
Elien Derveaux
LMLiesbet Mesotten
Liesbet Mesotten
Michiel ThomeerMichiel Thomeer
Michiel Thomeer
CMCriel Maarten
Criel Maarten
PAPeter Adriaensens
Peter Adriaensens
Lung cancer cells are well documented to rewire their metabolism and energy production networks to enable proliferation and survival in a nutrient-poor and hypoxic environment. Although metabolite profiling of blood plasma and tissue is still emerging in omics approaches, several techniques have shown potential in cancer diagnosis. In this paper, the authors describe the alterations in the metabolic phenotype of lung cancer patients. In addition, we focus on the metabolic cooperation between tumor cells and healthy tissue. Furthermore, the authors discuss how metabolomics could improve the management of lung cancer patients.

1 January 2022 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
QNQuentin Noirhomme
Quentin Noirhomme
ERElisa Rossetti
Elisa Rossetti
HMHanne Mariën
Hanne Mariën
DRDaimy Roebroek
Daimy Roebroek
MRMichiel Rooijakkers
Michiel Rooijakkers
WGWilfried Gyselears
Wilfried Gyselears